You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聖諾醫藥-B(02257.HK)期待在2023年擴展GalAhead遞送平台及其RNAi候選藥物進行臨牀試驗以治療各種肝臟代謝類疾病
格隆匯 06-21 22:26

格隆匯6月21日丨聖諾醫藥-B(02257.HK)發佈公吿,公司首席技術官Dmitry Samarsky博士將於第四屆RNA療法:從概念到臨牀專題討論會(The 4th Annual RNA Therapeutic:From Concept to Clinic Symposium)上分享公司專有GalAhead技術及其產品管線的雙靶向RNAi療法最新研發與應用擴展。專題討論會將於2022年6月22日至24日以線上會議形式舉行。

Sirnaomics專有的基於GalNAc-RNAi療法遞送平台GalAhead依託於獨特的RNA結構,可以沉默單個或多個mRNA靶點,特別是兩個關鍵技術組件mxRNA(小型化RNAi觸發器)及muRNA(多單位RNAi觸發器)。mxRNA由長度約為30 nt的單鏈寡核苷酸組成,旨在下調單類基因。而muRNA由多條單鏈寡核苷酸組成,允許同時沉默兩個或多個目標。Sirnaomics將於專題討論會展示上述兩種技術的數據,尤其是已在動物模型中獲得驗證的muRNA的雙靶點基因沉默活性,以及報吿基於GalAhead的治療項目取得的快速進展。

“Sirnaomics正致力於開發RNAi遞送技術以實現更高效率的治療應用。公司新型的GalAhead技術的單靶點與雙靶點的RNAi療法已經在齧齒動物和非人類靈長類動物模型中得到了反覆驗證”。 Sirnaomics創始人、董事會主席、執行董事、總裁兼首席執行官陸陽博士表示,“我們期待在2023年擴展我們的GalAhead遞送平台及其RNAi候選藥物進行臨牀試驗以治療各種肝臟代謝類疾病”。

Sirnaomics首席技術官Dmitry Samarsky博士表示:“自我們於2019年正式向公眾介紹了Sirnaomics的GalAhead技術以來,該技術被反覆證明是穩健且具有重現性的。有監於此,我們計劃在2022年底前提交首個候選產品的IND申請。今年我們已經提名了另外四個基於GalAhead遞送平台的開發性候選藥物,包括首個雙靶點分子,我們計劃在2022年底前新增更多的候選藥物

據悉,Sirnaomics是一家RNA療法生物製藥公司,公司候選產品處於臨牀前及臨牀階段,專注於探索及開發創新藥物,用於治療存在醫療需求及龐大市場機會的適應症。Sirnaomics是在中國和美國均擁有重要市場地位的首家臨牀階段RNA療法生物製藥公司,且是首家將其核心產品STP705的RNAi療法在腫瘤學領域取得積極IIa期臨牀結果的公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account